Next Generation Diagnostic
Advanced NGS for rare genetic disease diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
€8.0m | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 40 % | 31 % | (32 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (101 %) | (186 %) | (82 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (218 %) | (264 %) | (160 %) | 2 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Next Generation Diagnostic (NGD) is a spin-off from the Telethon Foundation, leveraging the expertise of researchers from the Telethon Institute of Genetics and Medicine (Tigem) in Pozzuoli, Naples. The company focuses on utilizing Next Generation Sequencing (NGS) technologies to improve the diagnostic success rate for rare genetic diseases and to develop new approaches for analyzing RNA from cancer patient biopsy samples. The primary goal is to standardize molecular genetic testing to provide rapid, accurate diagnoses and to identify biomarkers that enable personalized and targeted treatments for patients.
The company's project received significant financial support of €6,085,976 from the PON Research and Innovation 2014-2020 program, facilitated through the European Investment Bank (EIB). This funding was provided as risk finance in the form of equity and quasi-equity. NGD's business model appears to be centered on research and development to industrialize advanced NGS diagnostic methods and applications for pathological anatomy. An investment plan for 2019-2020 included the hiring of six full-time researchers to support this industrialization effort.
NGD operates within the Health Area and utilizes Industrial Biotechnology as a key enabling technology. The company, registered as Next Generation Diagnostic S.r.l., is headquartered in Pozzuoli (NA), Italy. By combining know-how in genetics, genomics, and bioinformatics from Tigem, NGD aims to be at the forefront of translating research into practical diagnostic solutions.
Keywords: Next Generation Sequencing, molecular diagnostics, rare genetic diseases, oncology diagnostics, personalized medicine, biomarker identification, genetic testing, RNA analysis, bioinformatics, pathological anatomy, Tigem, Telethon, industrial biotechnology